Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Por van Doorn, P A
Publicado em 1994

Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study.

Por Molenaar, D S, van Doorn, P A, Vermeulen, M
Publicado em 1997

Multifocal motor neuropathy with abrupt onset and spontaneous recovery

Por Bulens, C., Vermeij, F. H., van Doorn, P. A.
Publicado em 2007

Treatment of Guillain–Barré syndrome with mycophenolate mofetil: a pilot study

Por Garssen, M P J, van Koningsveld, R, van Doorn, P A
Publicado em 2007

Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies

Por van den Berg, L H, Franssen, H, Van Doorn, P A, Wokke, J
Publicado em 1997

Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies

Por Merkies, I, Schmitz, P, van der Meche, F G A, van Doorn, P A
Publicado em 2000

Decreased electrical excitability of peripheral nerves in demyelinating polyneuropathies.

Por Meulstee, J, Darbas, A, van Doorn, P A, van Briemen, L, van der Meché, F G
Publicado em 1997

Chronic motor neuropathies: response to interferon-β1a after failure of conventional therapies

Por Martina, I, van Doorn, P A, Schmitz, P, Meulstee, J, van der Meche, F G A
Publicado em 1999

Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies

Por Merkies, I, Schmitz, P, van der Meche, F G A, Samijn, J, van Doorn, P A
Publicado em 2002

Connecting impairment, disability, and handicap in immune mediated polyneuropathies

Por Merkies, I, Schmitz, P, van der Meche, F G A, Samijn, J, van Doorn, P A
Publicado em 2003

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.

Por Vermeulen, M, van Doorn, P A, Brand, A, Strengers, P F, Jennekens, F G, Busch, H F
Publicado em 1993

Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy

Por Martina, I, van Koningsveld, R, Schmitz, P, van der Meche, F G A, van Doorn, P A
Publicado em 1998

Early recognition of poor prognosis in Guillain-Barré syndrome

Por Walgaard, C., Lingsma, H.F., Ruts, L., van Doorn, P.A., Steyerberg, E.W., Jacobs, B.C.
Publicado em 2011

Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.

Por Jacobs, B C, van Doorn, P A, Groeneveld, J H, Tio-Gillen, A P, van der Meché, F G
Publicado em 1997

Ganglioside Mimicry of Campylobacter jejuni Lipopolysaccharides Determines Antiganglioside Specificity in Rabbits

Por Ang, C. W., Noordzij, P. G., de Klerk, M. A., Endtz, H. P., van Doorn, P. A., Laman, J. D.
Publicado em 2002

Fatigue in neuromuscular disorders: focus on Guillain–Barré syndrome and Pompe disease

Por de Vries, J. M., Hagemans, M. L. C., Bussmann, J. B. J., van der Ploeg, A. T., van Doorn, P. A.
Publicado em 2009

Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands

Por Koga, M, Ang, C, Yuki, N, Jacobs, B, Herbrink, P, van der Meche, F G A, Hirata, K, van Doorn, P A
Publicado em 2001

Amantadine for treatment of fatigue in Guillain‐Barré syndrome: a randomised, double blind, placebo controlled, crossover trial

Por Garssen, M P J, Schmitz, P I M, Merkies, I S J, Jacobs, B C, van der Meché, F G A, van Doorn, P A
Publicado em 2006

Fatigue: an important feature of late-onset Pompe disease

Por Hagemans, M. L. C., van Schie, S. P. M., Janssens, A. C. J. W., van Doorn, P. A., Reuser, A. J. J., van der Ploeg, A. T.
Publicado em 2007

Guillain-Barré Syndrome- and Miller Fisher Syndrome-Associated Campylobacter jejuni Lipopolysaccharides Induce Anti-GM(1) and Anti-GQ(1b) Antibodies in Rabbits

Por Ang, C. W., De Klerk, M. A., Endtz, H. P., Jacobs, B. C., Laman, J. D., van der Meché, F. G. A., van Doorn, P. A.
Publicado em 2001